The piperazine derivative AKU-005 (4-Benzhydrylpiperazin-1-yl) (1H-1,2,4-triazol-4-yl) methadone) has been shown in vitro to be a new potent inhibitor of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) enzyme activity in several areas of the nervous system involved in migraine pain signaling [25]. This evidence concerns the gene MGLL and migraine disorder.